Year : 2021  |  Volume : 8  |  Issue : 5  |  Page : 6-10

D-Dimer and thrombosis in COVID-19

Department of Haematology, Manchester University Hospitals, Oxford Road, Manchester, United Kingdom

Correspondence Address:
Jecko Thachil
Department of Haematology, Manchester University Hospitals, Oxford Road, Manchester
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijves.ijves_67_21

Rights and Permissions

The coronavirus disease 2019 (COVID-19) pandemic has taken medical community by surprise, but it also saw significant advances in understanding of infection induced coagulopathy. Pulmonary and macrovascular thrombosis is one of the hallmarks of this pandemic and has intrigued vascular surgeons world over. In this review, the lessons learnt from COVID-19 coagulopathy are summarised with some perspectives on role of newer concepts of immune mediated thrombosis and endothelial inflammation. D-dimers have become one of the most discussed inflammatory marker and also one of the commonest blood tests ordered in the COVID-19 pandemic. Its usefulness in management of COVID induced thrombosis has been a matter of debate and this article looks in to evidence based application of D-dimer in clinical practice. Role of Heparins, Direct Oral Anticoagulants (DOACs) and anti-platelets in prophylaxis and management of vascular thrombosis has also been summarised.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded177    
    Comments [Add]    

Recommend this journal